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Abstract
Lung cancer is the most lethal malignancy in the world, and each year thousands of people die from this disease. Early
detection has proven to increase the 5-year survival for this cancer in general, independent of the origination site in the
lung. To address this challenge, we have used cell-based SELEX (Systematic Evolution of Ligands by Exponential
Enrichment) to select a panel of aptamers capable of distinguishing lung adenocarcinoma cells from normal lung epithelial
cells. These aptamers bind at physiological and formalin-fixed conditions and display affinity for their targets with apparent
Kd’s in the nanomolar range. Our findings suggest that the selected aptamers have the potential to be used in clinical
settings, as well as to improve classification of nonsurgical specimens, another current challenge in lung cancer.
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Introduction
Lung cancer is the second most common type of cancer and the
leading cause of cancer-related deaths worldwide [1]. In the
United States, it is estimated that 226,160 new cases and 160,340
deaths will occur in 2012 (for Non-small cell and small cell
combined). Compared to other cancer types, lung neoplasms are
highly heterogeneous, with tumors displaying more than one
subtype as a common feature [2]. The vast majority of lung
neoplasms are carcinomas, which are generally classified as either
non-small cell lung carcinomas (NSCLC) or small cell lung
carcinomas (SCLC) on the basis of morphological analysis by
stained histological samples [3–4]. NSCLC is the most common
lung cancer type, comprising 85% of all lung cancer cases; yet it is
a more passive cancer type. NSCLC is composed of three different
subtypes: adenocarcinoma (ADC), squamous cell carcinoma
(SCC), and large cell carcinoma (LCL). On the other hand,
SCLC is less common, comprising 15% of all lung cancer cases,
but it is more aggressive. Smoking is a risk factor heavily associated
with lung cancer, specifically SCC [5–10]. Lung adenocarcinoma
is commonly developed by patients who have never smoked, and
genetic changes are often associated with its onset.
Since most people with lung cancer at the early stage do not
display symptoms, more than 70% of lung cancer cases are
diagnosed at later stages, for which the 5-year survival rate is small.
Therefore, research aimed at early detection, which is critical to
reducing mortality and morbidity, has turned to the development
of suitable aptamers. Aptamers are short, single-stranded DNA or
RNA oligonucleotides which are highly specific target recognition
elements based on their unique three-dimensional shapes [11–12].
While the process known as SELEX (Systematic Evolution of
Ligands by Exponential Enrichment) was originally used to select
aptamers against targets such as purified proteins [13–14], cell-
based SELEX has become the newest method of selecting
aptamers against whole cells, especially those aptamers targeting
surface proteins overexpressed in cancer cells.
Among their many advantages, aptamers have shown no, or
extremely low, immunogenicity, permitting in vivo studies using
these probes [15–18]. They have also been popularized as
alternatives to antibodies, because of aptamers’ low cost (no
animals necessary for production), easy chemical modification,
and cellular uptake capability. In addition, because aptamers are
small in length with generally 15 to 100 nucleotides (nt), they have
better tissue penetration compared to antibodies. In 2004,
Macugen, an anti-VEGF (Vascular Endothelial Growth Factor)
inhibitor, became the first aptamer approved by the Food and
Drug Administration (FDA) for Age-Related Macular Degenera-
tion (AMD) [19]. Other aptamers remain in clinical trials [20],
and have demonstrated great potential in the biomedical field,
including separation, drug delivery and target-probe measure-
ment. This report describes the use of cell-SELEX to select a panel
of aptamers capable of distinguishing between lung adenocarci-
noma and normal lung epithelial cells.
Results and Discussion
Since their discovery, aptamers have been generated against
different targets, including proteins, peptides, and living cells [21–
22]. To isolate aptamers capable of differentiating lung adeno-
carcinoma cells from normal lung epithelial cells, we used the cell-
based SELEX strategy. H23 lung adenocarcinoma and HBE 135-
E6/E7 normal epithelial lung were used as positive and negative
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cell lines, respectively. An initial ssDNA random library containing
approximately 1014 different sequences of 80 nucleotides (nt) was
enriched by sequential binding with the target cells, elution and
subsequent amplification by PCR for 18 rounds. These DNA
sequences could recognize H23 cell-surface membrane proteins
which are potential markers for targeted therapy. In earlier rounds
of the process, counter selection was introduced in order to remove
possible sequences binding common proteins on both target and
negative cell lines. This procedure was performed every other
round throughout the selection. Sequences binding to target cells
were eluted and PCR-amplified, after which ssDNA was recovered
and used to monitor the selection process by flow cytometry.
Because the ssDNA pools were enriched with sequences specific
for the target, an increase in fluorescence intensity was first noticed
in round 12 (Figure 1A), indicating that those sequences showed
better binding on the surface of H23 cells compared to the initial
library. As the selection progressed, the fluorescence intensity of
the subsequent pools gradually increased until a steady state in
fluorescence intensity was observed in rounds 17 and 18
(Figure 1B), indicating that maximum binding had been achieved.
In contrast, such enrichment was not observed when the enriched
pools were tested against normal lung epithelial cells (Figure 1D),
implying that sequences contained in those pools were capable of
distinguishing lung adenocarcinoma cells from normal lung
epithelial cells. Therefore, pools 14, 16 and 18 were selected to
be sequenced as aptamer candidates (Figure 1C).
The sequencing process began with the construction of the 454
sequencing library by PCR-addition of 454-specific primers to the
39- and 59-ends of the enriched pools. To identify the pool for each
sequence, a unique identification code (middle identification code,
MID) was also PCR-introduced to the 454 sequencing library.
The insertion of primers in the enriched pools was confirmed by
gel electrophoresis (data not shown). After 454 sequencing at the
UF ICBR core, around 7,000 sequences were retrieved and
analyzed. They were grouped on the basis of the MID
corresponding to the same pool, and primers were removed by a
Perl program. The sequences containing only the random region
were then aligned using the online program MAFTT 6.0 [23], and
six aptamer families corresponding to the most abundant
sequences were chosen as aptamer candidates. They were
chemically synthesized, biotin-labeled at the 39-end, purified by
HPLC, and quantified. All aptamers displayed binding with H23
lung adenocarcinoma cells, while no significant binding was
observed with the control cell line HBE 135 E6/E7, normal
epithelial lung cells (figure 2 and figure S1). These results indicate
that successful negative selection had been carried out and that
selected aptamers could distinguish between lung adenocarcinoma
and normal lung epithelial cells, an outcome which confers these
aptamers with the potential for use in lung cancer diagnosis,
monitoring tumor progression and treatment, or other relevant
applications.
All the selected aptamers showed binding affinities (apparent
Kd’s) to the H23 cell line in the nanomolar range (45–250 nM)
(Table 1 and figure S6). These results suggest that these aptamers
will be widely applicable, as they tightly bind to their target.
Further studies were carried out to characterize the selected
aptamers. The binding was further tested against lung cancer cell
lines, as well as other cell lines, including ovary and colon, as
shown in Table 2. Aptamers EJ2, EJ4 and ADE1 displayed some
recognition towards one or more of the following cell lines:
Figure 1. Progress of cell-SELEX methodology. Binding assay of pools 11–18 with H23 (A–B) and pools 15–18 with HBE135 E6/E7 (C). Flow
cytometry assay to monitor the binding of selected pool with H23 cells (target cells) and HBE135 E6/E7 (negative cells). The green curve represents
the background binding of unselected DNA library. For H23 cells, there was an increase in binding capacity of the pools as the selection progressed,
whereas there was little change for the control cells, HBE 135 E6/E7. Aim figure 1: The aim of this figure is to show how the cell-selection process
was enriched for H23 cell line but not for HBE135E6/E7 cell line.
doi:10.1371/journal.pone.0046222.g001
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TOV21G, DLD1, and H460. In the case of DLD1, a colon
adenocarcinoma cell line, it was interesting to see some
recognition by the selected aptamers, suggesting that a possible
common cell-surface target is present in these two cell lines, since
they belong to the same histological group. In a previous study in
our lab, the target protein of Sgc8 aptamer was demonstrated to
be PTK7 [24], a pseudo-kinase protein present in CEM cells (the
target cell line for that selection), as well as other cancers, including
ovary, lung, colon, breast and some leukemia cell lines, indicating
that common proteins can be present as a result of cancer [25–26].
Aptamers, EJ4 and ADE1 also showed particular specificity
towards the lung adenocarcinoma cell line with significant increase
in fluorescence intensity with respect to a random sequence, but
not to normal lung cells. These results suggest that these aptamers
could be used for lung cancer studies.
Flexible binding of aptamers at different temperatures can
expand their repertoire of applications. Since the selection was
performed at 4uC, we performed binding assays at 25uC and 37uC
(Figure 3 and Figure S2). As shown in Figure 3 and Figure S3,
aptamers ADE1, ADE2, EJ2, EJ5 and EJ7 conserved binding at
25uC and 37uC with fluorescence intensities similar to those at
4uC. This is particularly important in assays carried out under
physiological conditions, such as those assessing in vivo applications.
Cancer detection relies on the examination of tissue from
biopsies, which are fixed under chemical conditions to preserve the
integrity and antigenicity of tumor samples for later use. An
important assay in cancer diagnosis is immunostaining, in which
freshly dissected tissues are fixed prior to treatment with probes,
such as antibodies and aptamers, specifically for tumor markers.
Previous studies have shown that aptamers are capable of labeling
formalin-fixed paraffin tissue (FFPE) after deparaffinization and
antigen retrieval [27–28]. To determine the binding capability of
the selected aptamers under those conditions, cells were fixed with
10% formalin before incubation with labeled aptamers. As control
for these experiments, two known aptamers for leukemia, Sgc8
and TD05, and their corresponding binding cell lines were used to
show that the process of fixation does not produce any
fluorescence signal. Therefore any fluorescence detected should
be an indication of a binding event between the aptamers and its
target. As shown in figure S3, both controls retained their initial
binding profile, indicating that no artificial increment in fluores-
cence intensity occurred as a result of the fixing conditions. EJ2,
EJ5, EJ7, ADE1, and ADE2 aptamers maintained similar binding
to that displayed at 4uC (Figure 4) indicating that aptamers can
bind to their targets even under fixed conditions. These results
strongly suggest that selected aptamers have the potential to be
used as recognition molecules in clinical samples.
During cell selection, it is expected that aptamers interact
specifically with the surfaces of target cells; this behavior has been
reported in several studies [29–31]. In our experiment, cells were
treated with two enzymes, trypsin and proteinase K, for 3 and
10 minutes, washed with PBS, and then incubated with aptamers.
Figure 2. Characterization of selected aptamers. Flow cytometry assay for the binding of the selected aptamer EJ4 with H23 (target cell line)
and HBE135 E6/E7 (negative cell line). The green curve represents the background binding of a random sequence (library). Aim Figure 2: The aim of
this figure is to show that the candidate aptamers are indeed aptamers because they do bind with the positive cell line (H23), but do not bind with
the negative cell line (HBE135E6/E7).
doi:10.1371/journal.pone.0046222.g002
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All selected aptamers lost binding after treatment with both
proteases (Figure 5 and Figure S5. For all experiments, the
fluorescence intensity was significantly reduced; however, the
signal corresponding to assays with proteinase decreased to the
background, indicating that the target protein was removed
completely after treatment.
Conclusion
In conclusion, we have selected a panel of aptamers capable of
distinguishing lung carcinoma from normal lung epithelial cells.
These aptamers show high affinity towards the H23 cell line with
apparent Kd’s in the nanomolar range, but no detectable affinity
for normal lung epithelial cells. Aptamers also showed binding
under physiological conditions, as well as after chemical fixation,
suggesting that they can be applicable for in vivo experiments.
Proteinase treatment indicated that all aptamers in this panel bind
to proteins on the target cell surface. All these results suggest broad
potential applications of selected aptamers due to their specificity
for cancerous tissues but not for healthy cells. These aptamers can
also be used as molecular probes in clinical samples, such as freshly
extracted tumors and preserved histology specimens.
Materials and Methods
Library Design
The primers were design to satisfy the following characteristics:
a minimum hairpin structure, similar melting temperature (Tm)
and minimal base pairing. The primers and an 80-mer library
were designed using the IDT Oligo Analyzer 3.1 software [32].
The forward primer was labeled with Fluorescein Isothiocyanate
(FITC) at the 59-end, and the reverse primer was labeled with
Biotin at the 59-end. The library consisted of a randomized 44-nt
region flanked on the 59-end by the FITC- labeled primer and
flanked on the 39-end by the complementary unlabeled strand of
the reverse primer.
Instrumentation and Reagents
Libraries and primers were synthesized using the 3400 DNA
synthesizer (Applied Biosystems). All reagents for DNA synthesis
were purchased from Glen Research. DNA sequences were
purified by reversed phase HPLC (Varian Prostar using a C18
column and acetonitrile/triethylammonium acetate as the mobile
phase). PCR was performed on a Biorad Thermocycler, and all
reagents were purchased from Takara. The monitoring of the
selection process, binding assays, and determination of the
dissociation constants for the selected aptamers were performed
by flow cytometric analysis using a FACScan cytometer (BD
Immunocytometry Systems).
Cell Culture and Buffers
A total of eight established cell lines were used in this project, all
purchased from the American Tissue Culture Collection (ATCC).
H23 (CRL-5800) adenocarcinoma NSCLC was chosen as the
positive cell line, while the negative cell line chosen was HBE135-
E6/E7 (CRL-2741), normal human bronchial epithelial cells. The
H23 cell line was maintained in RPMI-1640 (ATCC) culture
medium supplemented with 10% Fetal Bovine Serum (FBS heat-
inactivated) and 1% penicillin-streptomycin. The normal bron-
chial lung cell line was maintained in a Keratin Serum-Free
Medium supplemented with 5 ng/mL human recombinant EGF,
0.05 mg/mL bovine pituitary extract (Invitrogen), 0.005 mg/mL
insulin, and 500 ng/mL hydrocortisone (Sigma-Aldrich). Cells
were incubated at 37uC under 5% CO2 atmosphere. Other cell
lines used for the selectivity assay were the CAOV3 and TOV21G
ovarian cancer cell lines, A549 lung adenocarcinoma, H520 lung
squamous cell carcinoma, H460 large cell lung carcinoma, and
DLD1 colon adenocarcinoma, and all were maintained according
to ATCC specifications. During selection, two buffers were used:
Washing Buffer (WB) (glucose 0.45% w/v and MgCl2 5 mM in
PBS) and Binding Buffer (BB) (1 mg/mL tRNA and 1 mg/mL
Table 1. Aptamer sequences and their dissociation constant (Kds) aptamers and pool %.
Name Sequences Kd (nM) % pool
ADE1 59AGT GGT CGA ACT ACA CAT CCT TGA ACT GCG GAA TTA TCT AC 39 7065 4,7
ADE2 59 GAG CCC TAT CTC ACA CCG CAC CCG CAA ACT ATC ATC CTACAT G 39 208638 0,53
EJ2 59 AGT GGT CGA ACT ACA CAT CCT TGA ACT GCG GAA TTA TCT AC 39 4565 7,3
EJ4 59 GAA GAC GAG CGG CGA GTG TTA TTA CGC TTG GAA ACA ACC CC 39 6068 10,2
EJ5 59 TAC GGG CTG GAT CCA CTG TTA CGG CGT GTA TCC GCT ATC AA 39 122611 0,71
EJ7 59 GAA GAC GAG CGG CGA GTG TTA TTA CGC TTG GAA ACA ACC CC 39 5568 5,8
doi:10.1371/journal.pone.0046222.t001
Table 2. Binding of Adenocarcinoma aptamers with other
cancer cell lines.
Cell line Name ADE1 ADE2 EJ2 EJ4 EJ5 EJ7
H23 Lung Adenocarcinoma +++ +++ ++++ ++++ ++ +++
HBE 135 Normal lung bronchial
cell
_ _ _ _ _ _
A549 Lung Adenocarcinoma ++ _ _ ++ _ _
H460 Large cell carcinoma _ _ ++ ++ _ _
H520 Squamous cell
carcinoma
_ _ _ _ _ _
CAOV3 Ovary adenocarcinoma _ _ _ _ _ _
TOV21G Ovary clear cell
carcinoma
++ _ ++ ++ _ _
DLD1 Colon adenocarcinoma _ _ +++ _ _ _
A threshold based on the fluorescence intensity of FITC in the flow cytometric
analysis was chosen so that 99% of cells incubated with the FITC-labeled
unselected DNA library would have lower fluorescence intensity than the
threshold. When the FITC-labeled aptamer was allowed to interact with the
cells, the percentage of the cells with fluorescence above the set threshold was
used to evaluate the binding capacity of the aptamer to the cells. (2) 0,10%,
10–35% +, 35–60% ++, 60–85% +++, .85% ++++.
doi:10.1371/journal.pone.0046222.t002
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BSA in WB). All previous reagents were purchased from Sigma-
Aldrich.
In vitro Selection
Because both cell lines used during the selection, adenocarci-
noma and normal human bronchial epithelial cells, are adherent
cell lines, the selection was performed on cell monolayers. About
20 nmol of the synthesized library was dissolved in 700 mL of
binding buffer. Before the process was initiated, the DNA pool was
denatured by heating at 95uC for five minutes, followed by rapid
cooling on ice. This forced the DNA sequences to adopt the most
favorable secondary structures. The DNA library was then
incubated with approximately 36106 target cells (H23) at 4uC
for 30 minutes. Subsequently, the cells were washed 3 times with
washing buffer to remove unbound sequences. Afterwards, the
bound sequences were recovered by heating at 95uC for
10 minutes and then centrifuging at 14,000 rpm to remove cell
debris.
The supernatant containing the DNA sequences was collected,
and the selected pool was PCR-amplified using FITC- and biotin-
labeled primers. Then, the generation of single strand DNA
(ssDNA) was achieved by incubation with streptavidin-coated
sepharose beads, obtaining the biotinylated strand. Counter
selection was carried out after observing some enrichment with
the target cells. In order to select aptamers with high specificity
and selectivity, the stringency of the washes (number of washes,
wash time, and volume of washing buffer) was increased in
subsequent rounds. The enrichment of the pools was monitored
using flow cytometry, sequenced with 454 technology, and
analyzed for aptamer candidates.
Flow Cytometric Analysis
Flow cytometry was used to monitor the enrichment of ssDNA-
bound sequences within the pools during the selection process, as
well as to evaluate the binding affinity and specificity of the
selected aptamers. The cultured cells were washed with WB before
and after incubation with the FITC ssDNA pool or selected DNA
sequences. Fluorescence intensity was determined on a FACScan
cytometer (BD Immunocytometry).
Figure 3. Aptamer binding at physiological conditions. Flow cytometry assay for selected aptamer EJ4 with H23 (target cell line) at
physiological temperature (37uC). Binding at 4uC was used as the positive control. The green curve represents the background binding of a random
sequence (library). Aim Figure 3: The aim of this figure is to demonstrate the binding of the selected aptamer EJ4 at 25uC and physiological
temperature, 37uC.
doi:10.1371/journal.pone.0046222.g003
Figure 4. Binding assays after fixation with 10% formalin. Binding assay of aptamers with H23 (target) cells pre-fixed with 10% formalin. Left
column shows the binding of selected aptamers with untreated cells at 4uC. Right column shows the binding of selected aptamers fixed cells. The
light green curve represents the background binding of a random sequence (library). Aim figure 4: The aim of this figure is to show the binding
capability of the selected aptamer EJ4 to cells that have been fixed with 10% formalin.
doi:10.1371/journal.pone.0046222.g004
Aptamers for Lung Cancer
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454 Sequencing and Analysis
After 18 rounds of selection, enriched pools 14, 16, and 18 were
chosen for sequencing. 454-specific primers and MID were PCR-
amplified and added to each sequence contained in each pool,
yielding a 125-bp product. The reactions were confirmed by gel
electrophoresis, cleaned using a PCR purification kit (Qiagen), and
submitted to the ICBR core at the University of Florida for
analysis.
Around seven thousand sequences were retrieved and analyzed.
First, sequences were grouped on the basis of their MID to
determine the corresponding enriched pool. Second, primers and
MID were removed by the Perl program in order to leave only the
random portion of the sequence for homology analysis with the
MAFFT 6.0 program.
Binding Assays
Different families of sequences retrieved from multiple sequence
analyses were synthesized, biotin-labeled at the 39-end, and tested
for binding with the positive and negative cell line. In addition, the
binding selectivity of each candidate was determined by incubat-
ing a 250 nM aptamer solution with 46105 target or counter-cells
for 30 minutes at 4uC. Cells were washed twice with WB and
incubated with streptavidin PE beads for 20 minutes at 4uC. After
washing, the cells were suspended in 200 mL WB. The fluores-
cence was determined with a FACScan cytometer by counting
36104 events. A randomized 80-mer sequence was used as a
control.
Binding Assays with fixed cells
To determine the ability of the aptamers to bind to fixed cells,
procedures similar to those described above were followed, with
the exception of the initial treatment of the cells. Briefly, adherent
H23 cells were detached from the dish by incubation with non-
enzymatic cell dissociation solution, and then fixed with 10%
formalin solution for 15 min at 4uC, washed, and suspended in
binding buffer.
Selectivity and Specificity Assays
To determine the specificity of these aptamers, different cell
lines, including CAOV3, DLD1, A549, H520, H460, and
TOV21G, were used in binding assays. Fluorescence intensity
was measured in order to confirm binding. All experiments
followed the flow cytometry experimental procedure described
above.
Temperature effect on aptamer binding
Selection was performed at 4uC.To determine if temperature
would affect the binding between aptamer and the target cells,
binding assays were carried out at two additional temperatures,
25uC and 37uC.
Determination of the dissociation constant
The affinity of the aptamer and its target was evaluated by
saturation assay. A sample containing 56105 H23 cells was
washed and incubated with different concentrations of aptamer
until saturation was achieved. All binding assays were repeated
three times, and the mean fluorescence intensity was calculated by
subtracting the fluorescence intensity of a scrambled sequence.
Data were collected, and the dissociation constant (Kd) was
obtained by fitting to a single binding site saturation model using
SigmaPlot 11.2v (Jandel, San Rafael, CA).
Protease Digestion
Trypsin and Proteinase K treatment. H23 cells were
washed twice with PBS and then incubated with 3 mL of either
0.05% trypsin/0.53 mM EDTA in Hank’s balanced salt solution
(HBSS), Cellgro, or 0.1 mg/mL proteinase K in PBS at 37uC for 3
and 10 minutes. FBS was added to quench the proteinase activity.
Cells were washed with WB and subsequently used for the binding
assays described above.
Supporting Information
Figure S1 Characterization of selected aptamers. Flow
cytometry assay for the binding of the aptamers ADE1, ADE2,
EJ2, EJ5 and EJ7 with H23 (target cell line) and HBE135 E6/E7
(negative cell line). The green curve represents the background
binding of a random sequence (library).
(TIF)
Figure S2 Aptamer binding in physiological conditions.
Flow cytometry assay for the binding of aptamers ADE1, ADE2,
EJ4, EJ5 and EJ7 with H23 (target cell line) at 25uC and 37uC. In
Figure 5. Binding Assays after proteinase treatment. Flow cytometry assay for selected aptamers after treatment with proteases; untreated
cells were used as positive control. (A) Cells treated with trypsin for 3 and 10 min prior binding with selected aptamer EJ4. (B) Cells treated with
proteinase K for 3 and 10 min prior binding with aptamer EJ4. Aim figure 5: The aim of this figure is to prove that the targets of the selected
aptamers are proteins present in the cell surface of the cancer cells (H23).
doi:10.1371/journal.pone.0046222.g005
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this set of experiments, binding at 4uC was used as positive control.
The green curve represents the background binding of a random
sequence (library).
(TIF)
Figure S3 Control experiment for Fixed treated cells.
Binding assay of aptamer Sgc8 with (A) CEM (target) cells and (B)
Ramos (control) cells before (left) and after (right) fixation, showing
that no artificial fluorescence signal was produced.
(TIF)
Figure S4 Binding assays after fixation with 10%
formalin. Binding assay of aptamers with H23 (target) cells
pre-fixed with 10% formalin. Left columns show the binding of
aptamer ADE1, ADE2, EJ2, EJ5 and EJ7 with untreated cells at
4uC. Right column shows the binding of the same aptamers EJ5
with fixed cells. The light green curve represents the background
binding of a random sequence (library).
(TIF)
Figure S5 Binding Assays after proteinase treatment.
Flow cytometry assay for aptamers ADE1 and ADE2, EJ5 and EJ7
after treatment with proteases; untreated cells were used as positive
control. (A) and (C) Cells treated with trypsin for 3 and 10 min
prior binding with aptamers ADE1 and ADE2, EJ5, and EJ7
respectively. (C) and (D) Cells treated with proteinase K for 3 and
10 min prior binding with aptamers respectively.
(TIF)
Figure S6 Apparent Kd’s for selected aptamers. Satura-
tion binding curves for selected aptamers ADE1, ADE2, EJ2, EJ5
and EJ7. Cells were incubated with different concentrations of the
aptamer in triplicate. The mean fluorescence intensity of
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